Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Some Websites May Not be Effective in Helping Pancreatic Cancer Patients Make Optimal Treatment Decisions

(American College Of Surgeons) Oct 18, 2016 - Cancer patients often turn to the Internet to find information about treatment options, but not all websites are created equal. Websites featuring pancreatic treatment modalities differ significantly in the way they present information based on therapy type, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
read press release 

Minimally Invasive Surgery for Challenging Liver Cases Compares Favorably with Open Operations

(American College Of Surgeons) Oct 17, 2016 - For patients who may benefit from a major liver operation to treat cancer, an open abdominal procedure is often the only option. However, a minimally invasive approach that avoids the large open incision may soon be a viable alternative, according to results from a multicenter study presented at the 2016 Clinical Congress of the American College of Surgeons (ACS).
read press release 

Contralateral Prophylactic Mastectomy is a Popular Treatment Choice among Breast Cancer Patients in an Online Health Community

(American College Of Surgeons) Oct 18, 2016 - Fearing recurrence, patients opted for an aggressive double mastectomy despite evidence that a lumpectomy or single mastectomy would also be effective.
read press release 

Celgene and Sage Bionetworks Announce Technology Collaboration to Develop Observational Study Using the Apple ResearchKit Framework

(Stockhouse) Oct 18, 2016 - Celgene Corporation and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of the burden of disease for patients living with chronic anemia due to myelodysplastic syndromes (MDS) or beta-thalassemia.
read article 

Cerulean Announces Technology Platform Collaboration

(Yahoo! Finance) Oct 19, 2016 - Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company has entered into a strategic collaboration with Novartis to develop NDC product candidates combining Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds directed at up to five targets.
read article 

Drug Company Falsely Claimed Patients Had Cancer, Feds Allege

(Hartford Courant) Oct 18, 2016 - A former executive of Insys Therapeutics has been criminally charged for leading a special "reimbursement unit" at the company that defrauded insurers into paying for a potent opioid pain medication by falsely claiming patients had cancer and other conditions needed for pre-approval.
read article 

Sanders’ Tweet on Drugmaker Ariad’s ‘Greed’ Sends Stock Plunging

(Bloomberg) Oct 14, 2016 - A 114-character tweet from Senator Bernie Sanders’ twitter account cost Ariad Pharmaceuticals Inc. investors as much as $387 million on Friday afternoon.
read article 

There’s a Breast Microbiome, and It’s Different In Women With Breast Cancer

(Washington Post/To Your Health) Oct 19, 2016 - Researchers from the Mayo Clinic have identified significant differences in the breast bacteria of women with and without breast cancer.
read article (free registration required) 

Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

(Yahoo! Finance) Oct 19, 2016 - Merck & Co., Inc., known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint.
read article 

Investigational Immunotherapy Was Safe, Tolerable, and Showed Some Activity Against Melanoma

(AACR) Oct 19, 2016 - The investigational immunotherapeutic IMC-20D7S was safe, well tolerated, and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a first-in-human phase I clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
read press release 

Roche's Lung Cancer Drug Wins U.S. Approval

(Reuters) Oct 18, 2016 - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this hotly contested market.
read article 

Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day

(Kite Pharma) Oct 19, 2016 - Kite Pharma, Inc. presented updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates and KTE-C19 launch readiness at its Investor Day in New York on October 18, 2016.
read corporate press release 

FDA Modifies Use of Erlotinib in NSCLC to Include Only Patients Whose Tumors Harbor EGRF Mutations

(ASCO in Action) Oct 18, 2016 - On October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations.
read article 

FDA Approves Atezolizumab for Advanced Non-Small Cell Lung Cancer

(ASCO in Action) Oct 18, 2016 - On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy.
read article 

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

(Genentech) Oct 18, 2016 - First and only anti-PDL1 cancer immunotherapy approved by the FDA for metastatic non-small cell lung cancer (NSCLC); approval based on survival benefit of TECENTRIQ compared to docetaxel chemotherapy, regardless of PD-L1 status.
read corporate press release 

Here Are 3 Big Projects The White House Cancer Moonshot Is Pursuing

(STAT) Oct 17, 2016 - Liquid biopsies. A “groundbreaking” Defense Department study. Partnerships with Lyft and Uber for patient transportation.
read article 

Study: Efforts to Improve Outpatient Care Have Failed In Critical Areas

(CBS News/HealthDay News) Oct 17, 2016 - Efforts to improve the quality of care in the United States have had little impact on many aspects of outpatient care, a new, sweeping analysis shows.
read article 

Biology, Not Location, Should Classify Periampullary Cancers

(Medscape Medical News) Oct 14, 2016 - Should periampullary adenocarcinomas be classified by their biology rather than their anatomic location? That's the basic question addressed by a new study from California investigators, published October 10 in JAMA Surgery.
read article (free registration required) 

FDA Awards 21 Grants To Stimulate Product Development For Rare Diseases

( Oct 17, 2016 - The U.S. Food and Drug Administration today announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases.
read press release 

PTC Therapeutics Stock Plummets 29% After FDA Denies Company's DMD Drug Appeal

(MarketWatch) Oct 17, 2016 - PTC Therapeutics Inc. shares plummeted 29.2% to $9.41 on Monday morning after the company said its appeal of a Food and Drug Administration's decision about its Duchenne muscular dystrophy drug had been denied.
read article 

Shares Of Lannett Tumble After FDA Moves To Withdraw Approval Of Generic ADHD Drug

(Forbes) Oct 17, 2016 - Shares of Lannett plunged by 12.9% on Monday after the Food & Drug Administration said it planned to withdraw approval of its generic treatment for attention deficit hyperactivity disorder.
read article 

Pfizer to Launch Cheaper Version Of J&J Immune Drug Remicade

( Press) Oct 18, 2016 - Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson's blockbuster immune disorder drug, Remicade.
read article 

NYU Langone's Research Leader Receives Prestigious Award From The National Cancer Institute

(Yahoo! News) Oct 17, 2016 - In recognition of her accomplishments, Dafna Bar-Sagi, PhD, has been named a recipient of the Outstanding Investigator Award, a highly prestigious honor presented by the National Cancer Institute (NCI).
read article 

How a Cancer Patient Gives Back to Her Doctor

(Wall Street Journal) Oct 17, 2016 - Bita Javadizadeh, diagnosed with a rare form of cancer, is raising funds to benefit the research of her oncologist, Memorial Sloan Kettering Cancer Center’s Dr. Ghassan Abou-Alfa.
read article (paid subscription required) 

The Oncology Pharmacist’s Role in Patient-Centered Care

(ACCCBuzz) Oct 14, 2016 - Not all patients can say they have a personal relationship with their pharmacist. Many patients come to us thinking about their pharmacy team at their local drug store, but oncology pharmacists do so much more!
read article